Plain-English translation of NCT05959356 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether cetuximab and envafolimab combined with an intensive chemotherapy regimen (called mFOLFOXIRI) works better than the standard treatment of cetuximab with a less intensive chemotherapy (called mFOLFOX6) for people with advanced colorectal cancer. The study focuses on a specific type of colorectal cancer that has particular genetic characteristics and has spread to other parts of the body but cannot be removed by surgery.
Standard chemotherapy for this type of advanced colorectal cancer helps some patients, but doctors want to know if adding this newer medication to a stronger chemotherapy regimen could help more people live longer or see their cancer shrink more effectively.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the new medication combination or standard treatment. You will receive induction chemotherapy (up to 8 cycles, typically given every two weeks) followed by ongoing maintenance therapy until your cancer progresses, side effects become too severe, or you choose to stop. You will have regular clinic visits for blood tests, imaging scans, and check-ups to monitor how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China